GILD Quote, Financials, Valuation and Earnings

Johnson & Johnson has a net margin of 19.72% compared to Gilead Sciences's net margin of 50.24%. Gilead Sciences's return on equity of 32.29% beat Johnson & Johnson's return on equity of 30.18%.

Gilead Sciences has a consensus price target of $116.77, signalling upside risk potential of 7.62%. On the other hand Johnson & Johnson has an analysts' consensus of $169.18 which suggests that it could grow by 12.95%. Given that Johnson & Johnson has higher upside potential than Gilead Sciences, analysts believe Johnson & Johnson is more attractive than Gilead Sciences.

Gilead Sciences has a beta of 0.291, which suggesting that the stock is 70.86% less volatile than S&P 500. In comparison Johnson & Johnson has a beta of 0.422, suggesting its less volatile than the S&P 500 by 57.846%.

Gilead Sciences has a quarterly dividend of $0.79 per share corresponding to a yield of 2.88%. Johnson & Johnson offers a yield of 3.35% to investors and pays a quarterly dividend of $1.30 per share. Gilead Sciences pays 816.25% of its earnings as a dividend. Johnson & Johnson pays out 84.05% of its earnings as a dividend. Johnson & Johnson's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future, but Gilead Sciences's is not.

Gilead Sciences quarterly revenues are $6.7B, which are smaller than Johnson & Johnson quarterly revenues of $21.9B. Gilead Sciences's net income of $1.3B is lower than Johnson & Johnson's net income of $11B. Notably, Gilead Sciences's price-to-earnings ratio is 22.84x while Johnson & Johnson's PE ratio is 16.66x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Gilead Sciences is 4.76x versus 4.07x for Johnson & Johnson. Usually stocks with elevated PS ratios are considered overvalued.

Eli Lilly and has a net margin of 19.72% compared to Gilead Sciences's net margin of 21.68%. Gilead Sciences's return on equity of 32.29% beat Eli Lilly and's return on equity of 78.25%.

Gilead Sciences has a consensus price target of $116.77, signalling upside risk potential of 7.62%. On the other hand Eli Lilly and has an analysts' consensus of $951.98 which suggests that it could grow by 24.81%. Given that Eli Lilly and has higher upside potential than Gilead Sciences, analysts believe Eli Lilly and is more attractive than Gilead Sciences.

Gilead Sciences has a beta of 0.291, which suggesting that the stock is 70.86% less volatile than S&P 500. In comparison Eli Lilly and has a beta of 0.404, suggesting its less volatile than the S&P 500 by 59.63%.

Gilead Sciences has a quarterly dividend of $0.79 per share corresponding to a yield of 2.88%. Eli Lilly and offers a yield of 0.73% to investors and pays a quarterly dividend of $1.50 per share. Gilead Sciences pays 816.25% of its earnings as a dividend. Eli Lilly and pays out 44.2% of its earnings as a dividend. Eli Lilly and's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future, but Gilead Sciences's is not.

Gilead Sciences quarterly revenues are $6.7B, which are smaller than Eli Lilly and quarterly revenues of $12.7B. Gilead Sciences's net income of $1.3B is lower than Eli Lilly and's net income of $2.8B. Notably, Gilead Sciences's price-to-earnings ratio is 22.84x while Eli Lilly and's PE ratio is 62.06x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Gilead Sciences is 4.76x versus 14.06x for Eli Lilly and. Usually stocks with elevated PS ratios are considered overvalued.

Moderna has a net margin of 19.72% compared to Gilead Sciences's net margin of -907.48%. Gilead Sciences's return on equity of 32.29% beat Moderna's return on equity of -29.23%.

Gilead Sciences has a consensus price target of $116.77, signalling upside risk potential of 7.62%. On the other hand Moderna has an analysts' consensus of $47.59 which suggests that it could grow by 83.75%. Given that Moderna has higher upside potential than Gilead Sciences, analysts believe Moderna is more attractive than Gilead Sciences.

Gilead Sciences has a beta of 0.291, which suggesting that the stock is 70.86% less volatile than S&P 500. In comparison Moderna has a beta of 1.858, suggesting its more volatile than the S&P 500 by 85.779%.

Gilead Sciences has a quarterly dividend of $0.79 per share corresponding to a yield of 2.88%. Moderna offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Gilead Sciences pays 816.25% of its earnings as a dividend. Moderna pays out -- of its earnings as a dividend.

Gilead Sciences quarterly revenues are $6.7B, which are larger than Moderna quarterly revenues of $107M. Gilead Sciences's net income of $1.3B is higher than Moderna's net income of -$971M. Notably, Gilead Sciences's price-to-earnings ratio is 22.84x while Moderna's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Gilead Sciences is 4.76x versus 3.21x for Moderna. Usually stocks with elevated PS ratios are considered overvalued.

Vertex Pharmaceuticals has a net margin of 19.72% compared to Gilead Sciences's net margin of 23.33%. Gilead Sciences's return on equity of 32.29% beat Vertex Pharmaceuticals's return on equity of -6.04%.

Gilead Sciences has a consensus price target of $116.77, signalling upside risk potential of 7.62%. On the other hand Vertex Pharmaceuticals has an analysts' consensus of $499.87 which suggests that it could grow by 13.38%. Given that Vertex Pharmaceuticals has higher upside potential than Gilead Sciences, analysts believe Vertex Pharmaceuticals is more attractive than Gilead Sciences.

Gilead Sciences has a beta of 0.291, which suggesting that the stock is 70.86% less volatile than S&P 500. In comparison Vertex Pharmaceuticals has a beta of 0.415, suggesting its less volatile than the S&P 500 by 58.544%.

Gilead Sciences has a quarterly dividend of $0.79 per share corresponding to a yield of 2.88%. Vertex Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Gilead Sciences pays 816.25% of its earnings as a dividend. Vertex Pharmaceuticals pays out -- of its earnings as a dividend.

Gilead Sciences quarterly revenues are $6.7B, which are larger than Vertex Pharmaceuticals quarterly revenues of $2.8B. Gilead Sciences's net income of $1.3B is higher than Vertex Pharmaceuticals's net income of $646.3M. Notably, Gilead Sciences's price-to-earnings ratio is 22.84x while Vertex Pharmaceuticals's PE ratio is 26.10x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Gilead Sciences is 4.76x versus 10.29x for Vertex Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.